A Managed Care Lens on JAK Inhibitors for the Treatment of Myelofibrosis

This activity was originally broadcast live as a satellite symposium held in conjunction with AMCP eLearning Days 2022.

Program Description

Myelofibrosis is a rare hematologic malignancy with related primary and secondary manifestations including polycythemia vera, essential thrombocythemia, and other myeloproliferative neoplasms. Mutations in the Janus kinase (JAK) 2 gene are present in approximately 50% of patients with myelofibrosis, and JAK inhibitors have since emerged as therapeutic targets. However, each JAK inhibitor has unique mechanisms of action and gene targets, making it important to distinguish their use in individual patients. This activity will examine the critical role of the pharmacist as part of the multidisciplinary team in determining disease- and patient-specific treatment plans to improve patient outcomes. Practical strategies for managed care professionals to incorporate approved and emerging JAK inhibitors into formularies for treatment of myelofibrosis will also be discussed.

Target audience: Health-system, managed care, and oncology pharmacists

Type of activity: Application
Release date: May 18, 2022
Expiration date: May 18, 2023

Time to complete activity: 1.0 hour
Fee: Free

Educational Objectives

At the completion of this activity, participants will be able to:

• Explain the etiology, pathophysiology, and prognostic scoring system of myelofibrosis
• Analyze the treatments for myelofibrosis along with the clinical data for Janus kinase inhibitors and pipeline-targeted therapies
• Interpret the quality of life and impact of financial toxicity for patients with myelofibrosis and the resources available to assist this population

Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.0 contact hour (0.10 CEU) under the ACPE universal activity number 0290-0000-22-257-H01-P. The activity is available for CE credit through May 18, 2023.

Instructions for Completing the Activity and Receiving CPE Credit

To receive CPE credit, participants must complete the pretest, review the activity in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date.

Disclosures

Faculty

Peter Campbell, PharmD, BCOP, has the following relevant financial relationships with commercial interests to disclose:

Consultant: Pharmacosmos

Stock/Shareholder: Cardiff Oncology, ContraFact, Cellectis, Oramed, Checkpoint Therapeutics

Melissa Pozotrigo, PharmD, BCOP, has no relevant financial relationships with commercial interests to disclose.

Pharmacy Times Continuing Education™ Planning Staff—Jim Palatine, RPh, MBA; Maryjo Dixon, RPh; Amy H. Seung, PharmD, BCOP, FHOPA; Kylie Ferrentino; Susan Pordon; Brianna Winters; and Chloe Taccetta have no relevant financial relationships with commercial interests to disclose.

An anonymous peer reviewer was used as part of content validation and conflict resolution. The peer reviewer has no relevant financial relationships with commercial interests to disclose.

Educational Disclaimer
CPE activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or they may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.

For questions about this internet CPE activity, please contact:
[email protected]
Privacy Policy and Terms of Use Information:
www.pharmacytimes.org/terms